Blue Jet Healthcare Limited (NSE:BLUEJET)
India · Delayed Price · Currency is INR | Market Cap | 102.78B +0.4% |
| Revenue (ttm) | 11.05B -6.3% |
| Net Income | 2.85B -19.0% |
| EPS | 16.11 -20.7% |
| Shares Out | 189.28M |
| PE Ratio | 33.71 |
| Forward PE | 29.44 |
| Dividend | 1.20 (0.22%) |
| Ex-Dividend Date | Sep 11, 2026 |
| Volume | 538,572 |
| Open | 540.30 |
| Previous Close | 535.75 |
| Day's Range | 532.35 - 546.90 |
| 52-Week Range | 325.00 - 647.80 |
| Beta | 0.66 |
| Analysts | Hold |
| Price Target | 563.00 (+3.68%) |
| Earnings Date | Nov 5, 2026 |
About Blue Jet Healthcare
Blue Jet Healthcare Limited engages in the manufacturing and sale of artificial sweeteners, pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in products. It provides contrast media intermediates, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related supplies to healthcare, pharma, animal feed, and food and beverages industries. It has operations in India, Norway... [Read more]
Financial Performance
In fiscal year 2026, Blue Jet Healthcare's revenue was 9.47 billion, a decrease of -8.03% compared to the previous year's 10.30 billion. Earnings were 2.48 billion, a decrease of -18.80%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BLUEJET stock is "Hold." The 12-month stock price target is ₹563.00, which is an increase of 3.68% from the latest price.
News
Blue Jet Healthcare Transcript: Q2 26/27
Q2 revenue reached a record INR 375 crore, with sequential growth across core businesses, while higher input costs pressured margins. Expansion advanced with Hyderabad R&D operational and Vizag planned as a phased growth platform.
Blue Jet Healthcare Quarterly report: Q2 2027
Blue Jet Healthcare has published its Q2 2027 quarterly earnings report on November 5, 2026.
Blue Jet Healthcare Slides: Q2 2027
Blue Jet Healthcare has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 5, 2026.
Blue Jet Healthcare Transcript: Q1 26/27
Q1 FY27 revenue rose 25% QoQ to INR 293 crore, with EBITDA of INR 98 crore and improved operating margin. API recovery and strategic investment support the outlook, while raw-material inflation and transit timing remain uncertainties.
Blue Jet Healthcare Slides: Q1 2027
Blue Jet Healthcare has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 3, 2026.
Blue Jet Healthcare Quarterly report: Q1 2027
Blue Jet Healthcare has published its Q1 2027 quarterly earnings report on August 3, 2026.
Blue Jet Healthcare Transcript: Q4 25/26
FY 2026 revenue fell 8% as PI/API destocking offset strong contrast media growth. FY 2027 visibility is improving, with double-digit contrast media growth expected, while major capacity investments and uncertain logistics costs shape the outlook.
Blue Jet Healthcare Slides: Q4 2026
Blue Jet Healthcare has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 25, 2026.
Blue Jet Healthcare Quarterly report: Q4 2026
Blue Jet Healthcare has published its Q4 2026 quarterly earnings report on May 25, 2026.
Blue Jet Healthcare Annual report: Q4 2026
Blue Jet Healthcare has published its Q4 2026 annual report on May 25, 2026.
Blue Jet Healthcare Transcript: Q3 25/26
Q3 revenue fell 40% YoY amid destocking, mix effects and one-time costs, while 9M revenue rose 3%. FY27 growth plans center on new contrast media capacity, backward integration and the CDMO pipeline, but recovery timing remains uncertain.
Blue Jet Healthcare Slides: Q3 2026
Blue Jet Healthcare has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 13, 2026.
Blue Jet Healthcare Quarterly report: Q3 2026
Blue Jet Healthcare has published its Q3 2026 quarterly earnings report on February 13, 2026.